Name: G17DT

---

Type: biotech

---

Groups: investigational

---

Indication: Intended for the treatment of various forms of cancer.

---

Accession Number: DB04914 ( DB04914)

---

Description: G17DT is a vaccine that neutralises gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan.

---

Structure:

---

Prescription Products: Not Available

---

Generic Prescription Products: Not Available

---

Over the Counter Products: Not Available

---

International Brands

• No Brands

---

Brand Names

• No Brands

---

Brand Mixtures

Brand Name	Ingredients

Brand Name	Ingredients

---

Categories

• Antineoplastic Agents
• Vaccines

Indication: Intended for the treatment of various forms of cancer.

---

Pharmacodynamics: Not Available

---

Mechanism of action: When administered, G17DT induces an immune response producing antibodies which bind with the peptide and also cross-react and neutralise gastrin 17 thus inhibiting the growth of gastrointestinal cancers and metastasis. In addition the product neutralizes glycine-extended gastrin 17 which is also a stomach and pancreatic cancer growth factor.

---

Absorption: Not Available

---

Volume of distribution: Not Available

---

Protein binding: Not Available

---

Metabolism: Not Available

---

Route of elimination: Not Available

---

Half life: Not Available

---

Clearance: Not Available

---

Toxicity: Not Available

---

Affected organisms

• Not Available

---

SNP Mediated Adverse Drug Reactions

• Not Available

Manufacturers:

• Not Available

---

Packagers:

• Not Available

---

Dosage forms

Form	Route	Strength

Form	Route	Strength

---

Prices

Unit description	Cost	Unit

Unit description	Cost	Unit

---

Patents

Country	Patent Number	Approved	Expires (estimated)

Drug Interactions

Drug	Interaction

Drug	Interaction

---

Food Interactions:

• Not Available

Kingdom: Organic Compounds

---

Super Class: Not Available

---

Class: Not Available

---

Sub Class: Not Available

---

Direct Parent: Not Available

---

Alternative Parents:

• Not Available

---

substituent:

• Not Available

Synthesis Reference: Not Available

---

General Reference: # Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT. BioDrugs. 2003;17(3):223-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12749761 # Gilliam AD, Watson SA: G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007 Mar;7(3):397-404. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17309331 # Ajani JA, Randolph Hecht J, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D: An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006 May 1;106(9):1908-16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16568451 # He AR, Marshall JL: Clinical experiences with G17DT in gastrointestinal malignancies. Expert Rev Anticancer Ther. 2006 Apr;6(4):487-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16613537 # Watson SA, Gilliam AD: G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin Biol Ther. 2001 Mar;1(2):309-17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11727538 # Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van Someren N, Pounder RE, Caplin ME: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol. 2002 Oct 15;20(20):4225-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12377966 # Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D: A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol. 2004 Jun;30(5):536-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15135483 # Takhar AS, Gilliam AD, Watson SA, Henwood M, Rowlands BJ, Broome P, Beckingham IJ: The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer. Eur J Surg Oncol. 2006 Mar;32(2):197-200. Epub 2005 Oct 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16246519

---

External Links:

Resource	Link

Resource	Link

---

ATC Codes:

• Not Available

---

AHFS Codes:

• Not Available

---

MSDS: Download